Lyra Therapeutics, Inc.

Lyra reported cash and cash equivalents of $58.1 million at September 30, 2021, down from $69.0 million at June 30, 2021, and said this should fund planned operations through 2022. Research and development expense was $7.1 million versus $3.7 million a year ago, general and administrative expense was $4.0 million versus $2.7 million, total operating expenses were $11.1 million versus $6.4 million, and net loss was $11.1 million versus $6.3 million. On a year-over-year basis, R&D, G&A, operating expenses, and net loss all increased as the company ramped for later-stage clinical programs and manufacturing. Forward, management expects only a slight uptick in R&D as manufacturing and clinical trial spending rises, while saying cash is sufficient through 2022. ENLIGHTEN-1 and ENLIGHTEN-2 for LYR-210 are expected to enroll over approximately 12 months, and BEACON for LYR-220 is expected to enroll through 2022.

Maria Palasis emphasized that the quarter showed “significant progress,” centered on stronger clinical evidence for LYR-210 and the upcoming transition into late-stage development. She highlighted durable post-removal benefit, the PK consistency data, and recognition from the American Rhinologic Society as validation of Lyra’s science and platform. Her tone was upbeat and strategic, framing CRS as a large underserved market and positioning LYR-210 and LYR-220 as potentially disease-modifying treatments.

Jason Cavalier reported quarter-end cash and cash equivalents of $58.1 million and said that should support planned operations through 2022. He said R&D rose to $7.1 million from $3.7 million and G&A rose to $4.0 million from $2.7 million, driven by tech transfer, manufacturing, headcount, consulting, and stock-based compensation. He also said total operating expenses were $11.1 million versus $6.4 million and net loss was $11.1 million versus $6.3 million, then guided to a slight overall increase in R&D as the company begins three trials.

Analysts focused on manufacturing scale-up, trial enrollment cadence, durability/retreatment, and the LianBio partnership. Management said current manufacturing is sufficient for the clinical studies, that Lyra will scale with its contract manufacturer and keep a backup source, and that ENLIGHTEN-1/2 enrollment should take about 12 months while BEACON should enroll through 2022. On durability, management said the ~50% retreatment assumption in internal models aligned with early LANTERN data, while Dr. Kern suggested the effect may reflect broad inflammatory suppression and possible tissue remodeling, but stressed the data are still small and not a cure.